BACKGROUND: Early disruption of the blood-brain barrier (BBB) due to severe ischemia can be detected by MRI T2* permeability imaging. In middle cerebral artery (MCA) infarction, pretreatment T2* permeability derangements have been found in 22% of patients and are powerful predictors of hemorrhagic transformation after revascularization therapy. The frequency, clinical correlates, and relation to hemorrhagic transformation of permeability derangements in posterior circulation have not been previously explored, and may differ as ischemia volume and collateral status are different between vertebrobasilar and MCA infarcts. METHODS: We analyzed clinical and pretreatment MRI data on consecutive patients undergoing recanalization therapy for acute vertebrobasilar ischemia at a medical center November 2001 through September 2009. Pretreatment MRI permeability images were derived from perfusion source imaging acquisitions. Permeability abnormality was detected as persisting increased signal intensity at later time points in perfusion MRI acquisition, indicating local accumulation of contrast caused by BBB leakage. RESULTS: Among the 14 patients meeting study entry criteria, mean age was 71.1 years and median pretreatment NIHSS was 20.5. Permeability imaging abnormality was present in 1 of the 14 patients (7%). Among 14 patients, post-treatment parenchymal hematoma occurred in one and more minor degrees of hemorrhagic transformation in four. The one patient with pretreatment permeability abnormality was the patient to develop post-treatment parenchymal hematoma (Fisher's exact test, P=0.07). CONCLUSION: Pretreatment permeability abnormality, an indicator of BBB derangements, is an infrequent finding in acute posterior circulation ischemic stroke and may be associated with an increased risk of parenchymal hematoma development undergoing recanalization therapy.
BACKGROUND: Early disruption of the blood-brain barrier (BBB) due to severe ischemia can be detected by MRI T2* permeability imaging. In middle cerebral artery (MCA) infarction, pretreatment T2* permeability derangements have been found in 22% of patients and are powerful predictors of hemorrhagic transformation after revascularization therapy. The frequency, clinical correlates, and relation to hemorrhagic transformation of permeability derangements in posterior circulation have not been previously explored, and may differ as ischemia volume and collateral status are different between vertebrobasilar and MCA infarcts. METHODS: We analyzed clinical and pretreatment MRI data on consecutive patients undergoing recanalization therapy for acute vertebrobasilar ischemia at a medical center November 2001 through September 2009. Pretreatment MRI permeability images were derived from perfusion source imaging acquisitions. Permeability abnormality was detected as persisting increased signal intensity at later time points in perfusion MRI acquisition, indicating local accumulation of contrast caused by BBB leakage. RESULTS: Among the 14 patients meeting study entry criteria, mean age was 71.1 years and median pretreatment NIHSS was 20.5. Permeability imaging abnormality was present in 1 of the 14 patients (7%). Among 14 patients, post-treatment parenchymal hematoma occurred in one and more minor degrees of hemorrhagic transformation in four. The one patient with pretreatment permeability abnormality was the patient to develop post-treatment parenchymal hematoma (Fisher's exact test, P=0.07). CONCLUSION: Pretreatment permeability abnormality, an indicator of BBB derangements, is an infrequent finding in acute posterior circulation ischemic stroke and may be associated with an increased risk of parenchymal hematoma development undergoing recanalization therapy.
Authors: Tobias Neumann-Haefelin; Silke Hoelig; Joachim Berkefeld; Jens Fiehler; Achim Gass; Marek Humpich; Andreas Kastrup; Thomas Kucinski; Olivera Lecei; David S Liebeskind; Joachim Rother; Charlotte Rosso; Yves Samson; Jeffrey L Saver; Bernhard Yan Journal: Stroke Date: 2006-08-24 Impact factor: 7.914
Authors: Martin Köhrmann; Eric Jüttler; Jochen B Fiebach; Hagen B Huttner; Stefan Siebert; Christian Schwark; Peter A Ringleb; Peter D Schellinger; Werner Hacke Journal: Lancet Neurol Date: 2006-08 Impact factor: 44.182
Authors: Oh Young Bang; Brian H Buck; Jeffrey L Saver; Jeffry R Alger; Sa Rah Yoon; Sidney Starkman; Bruce Ovbiagele; Doojin Kim; Latisha K Ali; Nerses Sanossian; Reza Jahan; Gary R Duckwiler; Fernando Viñuela; Noriko Salamon; J Pablo Villablanca; David S Liebeskind Journal: Ann Neurol Date: 2007-08 Impact factor: 10.422
Authors: Meng Law; Stanley Yang; Hao Wang; James S Babb; Glyn Johnson; Soonmee Cha; Edmond A Knopp; David Zagzag Journal: AJNR Am J Neuroradiol Date: 2003 Nov-Dec Impact factor: 3.825
Authors: Clinton D Morgan; Marcus Stephens; Scott L Zuckerman; Magarya S Waitara; Peter J Morone; Michael C Dewan; J Mocco Journal: Interv Neuroradiol Date: 2015-06-10 Impact factor: 1.610
Authors: E M Fanou; J Knight; R I Aviv; S-P Hojjat; S P Symons; L Zhang; M Wintermark Journal: AJNR Am J Neuroradiol Date: 2015-10-15 Impact factor: 3.825
Authors: Matthew R Amans; Daniel L Cooke; Maya Vella; Christopher F Dowd; Van V Halbach; Randall T Higashida; Steven W Hetts Journal: Interv Neuroradiol Date: 2014-02-10 Impact factor: 1.610